Ubiquitin-specific protease 15 promotes tumor cell invasion and proliferation in glioblastoma

Oncology Letters
Ke XuQianfeng Xia

Abstract

Glioblastoma multiforme (GBM) is one of the most aggressive types of brain tumor worldwide. Despite the advances made in treatment and research, the median survival time for GBM patients remains <1.5 years, providing impetus for the identification of potential novel therapeutic target genes to improve GBM treatment. The deubiquitinating enzyme ubiquitin specific peptidase 15 (USP15) has emerged as a pro-oncogenic factor; however, its function in GBM has yet to be fully elucidated. The present study sought to determine whether or not USP15 is implicated in GBM cell invasion and proliferation. Following the depletion of USP15 in U87-MG and U251-MG cells by lentivirus-mediated USP15 short hairpin RNA (shRNA), the invasiveness of glioma cells was investigated. The results of the present study demonstrated that glioma cells expressing USP15 shRNA exhibited significantly lower invasiveness than cells that did not express USP15 shRNA. Additionally, USP15 depletion led to the upregulation of E-cadherin and downregulation of the mesenchymal markers, N-cadherin and vimentin. Furthermore, the influence of USP15 on glioma cell proliferation was investigated and depletion of USP15 resulted in a marked reduction in cell proliferation. Taken ...Continue Reading

References

Oct 1, 1995·Current Opinion in Cell Biology·M Takeichi
Mar 6, 2004·Science·W James Nelson, Roel Nusse
May 22, 2004·Annals of the New York Academy of Sciences·Rachel B HazanKimita Suyama
Sep 12, 2006·Nature Cell Biology·Armando van der HorstBoudewijn M T Burgering
Oct 10, 2006·Biochimica Et Biophysica Acta·Panos Z Anastasiadis
Nov 18, 2006·Cell·Gaorav P Gupta, Joan Massagué
Feb 10, 2007·The EMBO Journal·Lauren F StevensonMark K Saville
Feb 24, 2007·The EMBO Journal·Katrin SchweitzerMichael Naumann
Nov 3, 2007·Genes & Development·Frank B FurnariWebster K Cavenee
Mar 7, 2008·Journal of Cell Science·Margaret J WheelockKeith R Johnson
May 17, 2008·Cancer Research·Tamer T OnderRobert A Weinberg
Jul 16, 2008·Archives of Neurology·Howard Colman, Ken Aldape
Aug 12, 2009·Biochemical and Biophysical Research Communications·Mingli XuMasahiko Kuroda
Aug 13, 2009·Molecular Cancer Therapeutics·Frédéric CollandLaurent Daviet
Oct 20, 2009·Oncogene·N Allende-VegaM K Saville
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P Savagner
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Jun 2, 2011·Cancer Research·Rudy BonaviaFrank B Furnari
Sep 29, 2011·Nature Cell Biology·Masafumi InuiStefano Piccolo
Oct 15, 2011·Oncogene·J M FraileC López-Otín
Oct 16, 2012·Biochemical Pharmacology·Luca PersanoGiampietro Viola
Mar 23, 2015·Cancer Letters·Ivy PawHui-Wen Lo
Aug 13, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Zhifei GuoBing Zhao

❮ Previous
Next ❯

Citations

Dec 17, 2020·Frontiers in Oncology·Nico ScholzJulien D F Licchesi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.